Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

12 evidence topics · 12 sources

Serum tryptase and plasma SCF in CSU: phase 1b, intravenous dosing every 4 or 8 weeks

“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The lowest dose (0.5 mg/kg) showed transient improvements in clinical activity that correlated with partial tryptase suppression, SCF increases, and subsequent recovery prior to the following dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Baseline serum tryptase in CSU compared with healthy participants, and response by baseline tryptase: phase 2 post hoc analysis
TimepointResponse definitionArea under the ROC curve for baseline serum tryptase
Week 12UAS7 = 0“0.49”
Week 12UAS7 ≤6“0.53”
Week 52UAS7 = 0“0.51”
Week 52UAS7 ≤6“0.56”
Serum tryptase and plasma SCF in healthy volunteers: single intravenous doses

“A single ascending dose (0.3, 1, 3, and 9 mg/kg), double‐blinded placebo‐controlled phase 1a human healthy volunteer study (n = 32) was conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX‐0159.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Tryptase reduction was manifest in all subjects dosed with CDX‐0159 at 24 h after the infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At the lowest dose of 0.3 mg/kg, plasma tryptase was reduced by approximately 50%, including the subject with high baseline tryptase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At higher doses, tryptase levels were reduced below the lower limit of assay quantitation (LLoQ) (1 ng/ml) in all CDX‐0159 treated subjects for at least 3 weeks at 1 mg/kg, 6–14 weeks at 3 mg/kg and over 18 weeks at 9 mg/kg (Figure 4B and Figure S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No significant change in tryptase was observed in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We observed dose‐proportional increases in SCF levels that mirrored the effects of CDX‐0159 on plasma tryptase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Together with the effect of the antibody on tryptase levels, these data provide additional evidence of systemic KIT saturation with CDX‐0159 at doses of 1 mg/kg and above.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Chronic inducible urticaria: kinetics of skin mast cell depletion and repopulation to Week 36
Eosinophilic esophagitis: esophageal intraepithelial mast cell counts at Week 12, phase 2

“This randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE.” (opens the source at this quote in a new tab)

“65 patients were randomly assigned on a 1:1 ratio to receive subcutaneous injections of barzolvolimab at 300 mg every 4 weeks or placebo during a 16-week placebo-controlled treatment phase.” (opens the source at this quote in a new tab)

“Peak mast cell counts (CD117 positive cells) per high power field (hpf) at baseline were 50.3 in the placebo arm and 55.4 in the barzolvolimab 300mg Q4W arm.” (opens the source at this quote in a new tab)

“At Week 12 the absolute change from baseline was -2.7 for placebo compared to -36.0 for barzolvolimab [Diff (95%CI): -33.3 (-44.1, -22.6); p=<0.0001)].” (opens the source at this quote in a new tab)

“Mast cells defined by tryptase staining also showed profound decreases at week 12 in barzolvolimab treated patients with sustained and deepening decreases observed at Week 28.” (opens the source at this quote in a new tab)

“Despite profound mast cell depletion, no definitive evidence of clinical improvement in EoE symptoms, as measured by the Dysphagia Symptom Questionnaire (DSQ) (p=0.33), or endoscopic scoring of EoE-related inflammation & fibrosis (EREFS) (p=0.95) were observed compared to placebo.” (opens the source at this quote in a new tab)

“There was also no difference observed in histological reduction in esophageal intraepithelial infiltration of eosinophils (p=0.57).” (opens the source at this quote in a new tab)

Nonclinical toxicology in cynomolgus monkeys: bone marrow, red blood cell mass, and hair color

“To support human trials, a GLP‐compliant toxicology study was performed with CDX‐0159 in cynomolgus monkeys with dose levels of 1, 10, and 75 mg/kg administered every two weeks for 13 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“CDX‐0159 was well tolerated with no significant changes in body weight, coagulation, clinical chemistry, ophthalmology, electrocardiography, respiratory, or neurological function during the treatment and recovery period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Observations attributed to CDX‐0159‐included minimal increases in the myeloid to erythroid ratio in bone marrow smears in the animals dosed at 10 and 75 mg/kg at the end of dosing (day 85), with evidence of recovery by day 141 despite continued drug exposure in the recovery period (Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, recoverable minimal/mild decreases in red blood cell mass parameters were observed (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Hair color changes were noted in some high‐dose‐treated animals, consistent with inhibition of KIT activity in follicular melanocytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote